VERA Vera Therapeutics Inc

Vera Therapeutics (VERA) recently completed a US$260.87 million follow-on offering and announced the departure of its Chief Legal Officer. This capital raise significantly extends the company's financial runway, reshaping the risk profile rather than the core investment narrative, which still hinges on clinical progress and regulatory outcomes. The leadership change is noted, but its immediate impact is seen as less critical than ongoing product development and commercialization efforts.

Latham & Watkins LLP represented Vera Therapeutics in a US$300 million underwritten public offering of its Class A common stock. The offering involved 7,058,824 shares at US$42.50 per share, including the underwriters' full exercise of their option to purchase additional shares. The offering successfully closed on December 11, 2025.

Latham & Watkins LLP represented Vera Therapeutics, Inc. in a US$300 million underwritten public offering of its Class A common stock. The offering involved 7,058,824 shares at US$42.50 per share, including the underwriters' full exercise of their option to purchase additional shares. The transaction, which closed on December 11, 2025, involved a multidisciplinary Latham & Watkins team advising the late clinical-stage biotechnology company.

Vera Therapeutics announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at $42.50 per share, expecting to raise approximately $261 million in gross proceeds. The company also granted underwriters a 30-day option to purchase additional shares. The offering is anticipated to close on December 11, 2025.

Vera Therapeutics announced a public offering of 6,138,108 shares of Class A common stock at an offering price of $42.50 per share, aiming to raise approximately $260.9 million in gross proceeds. The underwriters have an option to purchase an additional 920,716 shares, with the closing expected on December 11, 2025. This information is based on an SEC filing from December 9, 2025.

Vera Therapeutics, a biotechnology company, has priced a public offering of 6.1 million shares of Class A common stock at $42.50 per share, aiming to raise approximately $261 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 920,716 shares and is expected to close on December 11, 2025. The company specializes in developing treatments for immunologic diseases, with lead product candidate atacicept.